The downgrade was influenced by the expectation that Evonik's profit recovery may lag behind its peers despite the company's resilient performance throughout 2024. Morgan Stanley acknowledged the ...
The firm also adjusted the price target to €18.60, a decrease from the previous target of €22.00. The downgrade was influenced by the expectation that Evonik's profit recovery may lag behind its peers ...